Zejing pharmaceutical: an advance loss of 372 million yuan to 455 million yuan in 2021

China's First Oral COVID-19 Antiviral Medicine in Dispute

An obscure Chinese company called Genuine Biotech(Chinese: 真实生物) was suddenly put under the spotlight on July 25 when the Chinese authority announced the conditional approval of the company's application for adding the treatment of COVID-19 as a new indication of Azvudine under the special review and approval procedures for drug registration.

Kingsoft Cloud Q4 2022 Achieve Revenue CNY 2.13 billion, Down 19.9% YOY

With the iteration of the large generic model, AI field is likely to continue to develop rapidly, if Kingsoft Office to build their own models and algorithms, building WPS from office software into a new generation of AI assistant, then it is also a great advantage for Kingsoft Cloud(Chinese: 金山云).

Surgerii Robotics: Single-Port Surgical Robots Poised to Transform Surgery

The worldwide surgical robotic market is expected to grow at a booming CAGR of 5.8% during 2022 to 2030, rising from USD 5.05 billion in 2022 to USD 21.41 billion in 2030. Of which, the single-port surgical robots that result in less pain, fewer scars, and quicker recovery, have tremendous up potential.

2022 SMIC Net Income Up 13% YOY, Revenue Up 39% YOY

SMIC(Chinese:中芯国际): In terms of industry patterns, the international environment of the semiconductor industry is undergoing a new round of changes, with the global supply chain showing a trend of regionalization.

Junshi Biosciences Receives NMPA Approval of sNDA for Toripalimab

The study data showed that compared to chemotherapy alone, toripalimab in combination with chemotherapy in the first-line treatment of patients with advanced NSCLC without EGFR/ALK mutations could significantly improve the PFS and the OS of patients with a manageable safety profile regardless of PD-L1 expression status.